Dengue is a mosquito-borne infection of growing international public health importance, found in both tropical and sub-tropical regions, predominantly in urban and semi-urban areas. Severe dengue, a potentially lethal complication, affects most Asian and Latin-American countries and has become a leading cause of hospitalization and death among children in the region.
With no specific drug candidate for dengue treatment in sight, TDR supported an analysis of the dengue drug research portfolio which is available on the web (see below) to help identify candidates, facilitate interactions and promote R&D.
TDR research is also identifying how to improve classification and surveillance and outbreaks. A revised disease classification lead by TDR and WHO’s department of neglected tropical diseases is being tested and adopted in countries.
- Comments on The Guidance Framework for testing genetically modified mosquitoes under review
- Dengue control support through eco-bio-social approach
Nine projects to find new solutions to dengue and Chagas disease
Dengue vector control research completed in Asia
Eco-bio-social determinants of dengue vector breeding: a multicountry study in urban and periurban Asia
Dengue drug research portfolio
- More information on dengue
- Headway on dengue surveillance and outbreak response
- WHO estimates investments needed for neglected tropical diseases
- Bangladesh beats a deadly scourge
- Single dose treatment for visceral leishmaniasis can be effectively given in rural public hospitals
- Guidelines needed to predict, detect and manage dengue outbreaks
- New series on helminth infections R&D agenda